BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Initiates Patient Dosing in Phase I/IIa Combination Study Targeting Advanced Breast Cancer
Patient dosing has commenced in a combination study of Bria-IMT with KEYTRUDA or YERVOY in advanced breast cancer Company recently announced positive proof of concept data in the Phase I/IIa study of Bria-IMT in advanced breast cancer patients, which indicated excellent targeted anti-tumor activity and outstanding safety and tolerability KEYTRUDA and YERVOY are highly recognized for their potent immune boosting properties, which validates BriaCell's strategy to use these therapeutics in its combination study BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company engaged in developing targeted and safe approaches for cancer management, recently announced (http://ibn.fm/Hej9T) that it has initiated patient dosing in…